Cellectis Licenses Stem Cell Patents | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today said that it has licensed intellectual property covering induced Pluripotent Stem Cells (iPSCs) from iPS Academia Japan.

The non-exclusive licensing deals cover research conducted by Shinya Yamanaka of the Center for iPS Cell Research and Application at Kyoto University in Japan. iPS Academia Japan is an affiliate of Kyoto University established in 2008 to manage IP covering iPSC technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.